StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84
February 12, 2019 6:53 AM
RBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald
February 12, 2019 7:14 AM
Gilead Sciences's (GILD) STELLAR Failure Was Expected, Reit Neutral At Baird
February 12, 2019 6:39 AM
Gilead (GILD) calls active into late stage NASH study fails
February 12, 2019 4:58 AM
Options expected to have increasing volume: CHGG EA MGI GILD TAP NVDA KO
February 12, 2019 4:31 AM
UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral
February 12, 2019 2:50 AM
UPDATE: Wells Fargo Downgrades Gilead Sciences (GILD) to Market Perform
February 12, 2019 1:33 AM
After-Hours Movers 02/11: (RLGT) (CHGG) (VKTX) Higher; (VRNS) (LABL) (CMP) (more...)
February 11, 2019 5:27 PM
Gilead Sciences (GILD) Falls 4% After-Hours Following Failure of Cirrhosis Study
February 11, 2019 4:33 PM
Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to NASH Doesn't Meet Primary Endpoint
February 11, 2019 4:32 PM
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 11, 2019 4:30 PM
